vela

Impact

Cross-frontier impact.

Reviewer-declared dependency links between findings on three Alzheimer frontiers, filtered to accepted-core on the source side. Each row is one typed propagation: how an accepted finding on one frontier rests on, or extends, a finding on a peer frontier.

5
cross-frontier
links
4
accepted to
accepted
1
accepted to
unreviewed
3
frontiers
in scope

By link type.

Edges.

Filtered to accepted-core only on either side. Drafts and needs_revision findings are excluded.

From Link To Note
vf_1731753d816fb7d0 early-ad In TRAILBLAZER-ALZ 2, donanemab slowed CDR-SB progression by 0.67 points at 76 w depends accepted vf_29671540d388fc5d anti-amyloid The minimum clinically important difference for CDR-SB in early Alzheimer's dise Donanemab CDR-SB effect of -0.67 is calibrated against the MCID anchor declared in anti-amyloid translation.
vf_439b33c0ec425686 early-ad Hippocampal blood-brain barrier breakdown measured by DCE-MRI Ktrans is elevated depends accepted vf_8108c9642038749a bbb Interactive effects of blood-brain barrier breakdown and Alzheimer's disease bio Nation 2019 hippocampal BBB Ktrans elevation feeds the BBB-AD biomarker interaction analysis on cognitive decline.
vf_572f67e17d14dd9b early-ad The minimum clinically important difference (MCID) for CDR-SB in early Alzheimer depends accepted vf_29671540d388fc5d anti-amyloid The minimum clinically important difference for CDR-SB in early Alzheimer's dise MCID for CDR-SB scope anchor depends on the MCID finding in anti-amyloid translation; calibration cohort here uses the same anchor.
vf_84ebd5a5ef97eba6 early-ad Donanemab efficacy on iADRS at 76 weeks is larger in the low or medium tau patho depends accepted vf_29671540d388fc5d anti-amyloid The minimum clinically important difference for CDR-SB in early Alzheimer's dise iADRS stratification depends on a calibrated decline anchor; MCID for CDR-SB serves as the bridge anchor.
vf_84ebd5a5ef97eba6 early-ad Donanemab efficacy on iADRS at 76 weeks is larger in the low or medium tau patho extends unreviewed vf_0f4099b0c5f58629 anti-amyloid Influence of patient characteristics on efficacy and safety of anti-amyloid mono Tau-PET stratified efficacy in TRAILBLAZER-ALZ 2 extends the anti-amyloid translation efficacy/safety meta-analysis with a calibration-anchored stratification.

Compiled at 2026-05-09T00:57:19Z from exports/cross-frontier-impact.v1.json. Read-only view; the substrate event log is the source of truth.